Cost-effectiveness Analysis of Rituximab Maintenance Treatment in Patients With Follicular Lymphoma who Respond to First Line Induction Therapy in Portugal
Introduction: To perform a cost-effectiveness analysis of follicular lymphoma maintenance treatment after first-line induction with rituximab compared to observation in Portugal. Methods: A Markov follicular lymphoma model was developed with four health states: progression free survival on first an...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Formifarma, LDA.
2016-01-01
|
| Series: | Revista Portuguesa de Farmacoterapia |
| Subjects: | |
| Online Access: | http://revista.farmacoterapia.pt/index.php/rpf/article/view/90 |
| _version_ | 1819052307332988928 |
|---|---|
| author | Susana Carvalho Marília Gomes Herlander Marques Catarina Pereira Darío Rubio-Rodríguez Carlos Rubio-Terrés Carlos Sottomayor |
| author_facet | Susana Carvalho Marília Gomes Herlander Marques Catarina Pereira Darío Rubio-Rodríguez Carlos Rubio-Terrés Carlos Sottomayor |
| author_sort | Susana Carvalho |
| collection | DOAJ |
| description | Introduction: To perform a cost-effectiveness analysis of follicular lymphoma maintenance treatment after first-line induction with rituximab compared to observation in Portugal.
Methods: A Markov follicular lymphoma model was developed with four health states: progression free survival on first and second lines, progression and death. The transition probabilities between health states were obtained from the PRIMA and EORTC20981 clinical trials and the health states utilities from the literature. The analysis considered the Portuguese National Health Service perspective and includes only direct costs. Resource consumption was estimated by a Portuguese clinical expert panel. The unit costs (€ in 2014) were estimated using Portuguese official databases. Deterministic and probabilistic analyses were performed.
Results: In the base case, for a time horizon of 10 years, the cost per life year gained and per quality-adjusted
life-year were € 10,634 and € 10,664, respectively. The sensitivity analyses confirmed the stability of the base case for time horizons of 20 and 30 years, varying between € 7,430 and € 7,155. Maintenance with rituximab is cost-effective for a time horizon of 5.5 years (cost per quality-adjusted life-year gained of € 23,616).
Conclusion: According to the present model rituximab maintenance treatment of follicular lymphoma patients that respond to first line induction therapy in comparison with observation is cost-effective in Portugal. |
| first_indexed | 2024-12-21T12:17:45Z |
| format | Article |
| id | doaj.art-e7dd0bb0155848d2b2fc7d37563f977f |
| institution | Directory Open Access Journal |
| issn | 1647-354X 2183-7341 |
| language | English |
| last_indexed | 2024-12-21T12:17:45Z |
| publishDate | 2016-01-01 |
| publisher | Formifarma, LDA. |
| record_format | Article |
| series | Revista Portuguesa de Farmacoterapia |
| spelling | doaj.art-e7dd0bb0155848d2b2fc7d37563f977f2022-12-21T19:04:23ZengFormifarma, LDA.Revista Portuguesa de Farmacoterapia1647-354X2183-73412016-01-01811725Cost-effectiveness Analysis of Rituximab Maintenance Treatment in Patients With Follicular Lymphoma who Respond to First Line Induction Therapy in PortugalSusana Carvalho0Marília Gomes1Herlander Marques2Catarina Pereira3Darío Rubio-Rodríguez4Carlos Rubio-Terrés5Carlos Sottomayor6Serviço de Hematologia, Instituto Português de Oncologia de Lisboa, Francisco Gentil, E.P.E., Lisboa, PortugalServiço de Hematologia Clínica, Centro Hospitalar e Universitário de Coimbra, Coimbra, PortugalServiço de Oncologia Médica, Hospital de Braga, Braga, PortugalMarket Access, Roche Farmacêutica Química, Lda., Amadora, PortugalHEALTH VALUE, Madrid, EspanhaHEALTH VALUE, Madrid, EspanhaServiço de Oncologia, Hospital Pedro Hispano, Matosinhos, PortugalIntroduction: To perform a cost-effectiveness analysis of follicular lymphoma maintenance treatment after first-line induction with rituximab compared to observation in Portugal. Methods: A Markov follicular lymphoma model was developed with four health states: progression free survival on first and second lines, progression and death. The transition probabilities between health states were obtained from the PRIMA and EORTC20981 clinical trials and the health states utilities from the literature. The analysis considered the Portuguese National Health Service perspective and includes only direct costs. Resource consumption was estimated by a Portuguese clinical expert panel. The unit costs (€ in 2014) were estimated using Portuguese official databases. Deterministic and probabilistic analyses were performed. Results: In the base case, for a time horizon of 10 years, the cost per life year gained and per quality-adjusted life-year were € 10,634 and € 10,664, respectively. The sensitivity analyses confirmed the stability of the base case for time horizons of 20 and 30 years, varying between € 7,430 and € 7,155. Maintenance with rituximab is cost-effective for a time horizon of 5.5 years (cost per quality-adjusted life-year gained of € 23,616). Conclusion: According to the present model rituximab maintenance treatment of follicular lymphoma patients that respond to first line induction therapy in comparison with observation is cost-effective in Portugal.http://revista.farmacoterapia.pt/index.php/rpf/article/view/90Cost-Benefit Analysis; Follicular Lymphoma; Portugal; Ritu |
| spellingShingle | Susana Carvalho Marília Gomes Herlander Marques Catarina Pereira Darío Rubio-Rodríguez Carlos Rubio-Terrés Carlos Sottomayor Cost-effectiveness Analysis of Rituximab Maintenance Treatment in Patients With Follicular Lymphoma who Respond to First Line Induction Therapy in Portugal Revista Portuguesa de Farmacoterapia Cost-Benefit Analysis; Follicular Lymphoma; Portugal; Ritu |
| title | Cost-effectiveness Analysis of Rituximab Maintenance Treatment in Patients With Follicular Lymphoma who Respond to First Line Induction Therapy in Portugal |
| title_full | Cost-effectiveness Analysis of Rituximab Maintenance Treatment in Patients With Follicular Lymphoma who Respond to First Line Induction Therapy in Portugal |
| title_fullStr | Cost-effectiveness Analysis of Rituximab Maintenance Treatment in Patients With Follicular Lymphoma who Respond to First Line Induction Therapy in Portugal |
| title_full_unstemmed | Cost-effectiveness Analysis of Rituximab Maintenance Treatment in Patients With Follicular Lymphoma who Respond to First Line Induction Therapy in Portugal |
| title_short | Cost-effectiveness Analysis of Rituximab Maintenance Treatment in Patients With Follicular Lymphoma who Respond to First Line Induction Therapy in Portugal |
| title_sort | cost effectiveness analysis of rituximab maintenance treatment in patients with follicular lymphoma who respond to first line induction therapy in portugal |
| topic | Cost-Benefit Analysis; Follicular Lymphoma; Portugal; Ritu |
| url | http://revista.farmacoterapia.pt/index.php/rpf/article/view/90 |
| work_keys_str_mv | AT susanacarvalho costeffectivenessanalysisofrituximabmaintenancetreatmentinpatientswithfollicularlymphomawhorespondtofirstlineinductiontherapyinportugal AT mariliagomes costeffectivenessanalysisofrituximabmaintenancetreatmentinpatientswithfollicularlymphomawhorespondtofirstlineinductiontherapyinportugal AT herlandermarques costeffectivenessanalysisofrituximabmaintenancetreatmentinpatientswithfollicularlymphomawhorespondtofirstlineinductiontherapyinportugal AT catarinapereira costeffectivenessanalysisofrituximabmaintenancetreatmentinpatientswithfollicularlymphomawhorespondtofirstlineinductiontherapyinportugal AT dariorubiorodriguez costeffectivenessanalysisofrituximabmaintenancetreatmentinpatientswithfollicularlymphomawhorespondtofirstlineinductiontherapyinportugal AT carlosrubioterres costeffectivenessanalysisofrituximabmaintenancetreatmentinpatientswithfollicularlymphomawhorespondtofirstlineinductiontherapyinportugal AT carlossottomayor costeffectivenessanalysisofrituximabmaintenancetreatmentinpatientswithfollicularlymphomawhorespondtofirstlineinductiontherapyinportugal |